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Backgrounds: A new highly pathogenic human coronavirus (CoV), Middle East respiratory syndrome coronavirus
(MERS-CoV), has emerged in Jeddah and Saudi Arabia and quickly spread to some European countries since
September 2012. Until 15 May 2014, it has infected at least 572 people with a fatality rate of about 30% globally.
Studies to understand the virus and to develop antiviral drugs or therapy are necessary and urgent. In the present
study, MERS-CoV papain-like protease (PLpro) is expressed, and its structural and functional consequences are elucidated.
Results: Circular dichroism and Tyr/Trp fluorescence analyses indicated that the secondary and tertiary structure of
MERS-CoV PLpro is well organized and folded. Analytical ultracentrifugation analyses demonstrated that MERS-CoV PLpro
is a monomer in solution. The steady-state kinetic and deubiquitination activity assays indicated that MERS-CoV PLpro
exhibits potent deubiquitination activity but lower proteolytic activity, compared with SARS-CoV PLpro. A natural
mutation, Leu105, is the major reason for this difference.
Conclusions: Overall, MERS-CoV PLpro bound by an endogenous metal ion shows a folded structure and potent
proteolytic and deubiquitination activity. These findings provide important insights into the structural and functional
properties of coronaviral PLpro family, which is applicable to develop strategies inhibiting PLpro against highly pathogenic
coronaviruses.
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In September 2012, a new highly pathogenic human cor-
onavirus (CoV)1, Middle East respiratory syndrome cor-
onavirus (MERS-CoV), has emerged in Jeddah and
Saudi Arabia and quickly spread to some European
countries [1-3]. The virus causes symptoms similar to
Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV), yet involving an additional component of acute
renal failure [4]. Until 15 May 2014, it has infected at
least 572 people with a fatality rate of about 30% globally
(World Health Organization, global alert and response,
http://www.who.int/csr/don/2014_05_15_mers/en/). Re-
cently, human-to-human transmission of MERS-CoV
has been confirmed; albeit, a serological study of major* Correspondence: fish3970@gmail.com; cychou@ym.edu.tw
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unless otherwise stated.livestock suggested dromedary camels also to be a possible
host [5,6]. Nevertheless, these findings indicate that the
virus have the opportunity to spread globally and pose a
significant threat to world health and the economy. There-
fore, studies to understand the virus and to develop anti-
viral drugs or therapy are necessary and urgent.
Like other CoVs, the MERS-CoV nonstructural poly-
proteins (pp1a and pp1ab) are cleaved by two types of
viral cysteine proteases, a main protease (EC 3.4.22.69)
and a papain-like protease (PLpro) (EC 3.4.22.46) [7]. This
processing is considered to be a suitable antiviral target be-
cause it is required for viral maturation. Unfortunately, ini-
tial screening of the existing SARS-CoV PLpro inhibitor, a
benzodioxolane derivative against MERS-CoV PLpro, re-
vealed no significant inhibition [7]. The difference repre-
sents the requirement of further understanding the MERS-
CoV PLpro. In addition to proteolytic activity, similar to
those of SARS-CoV, NL63-CoV and murine hepatitis virus,
MERS-CoV PLpro acts on both deubiquitination and
ISG15-linked ISGylation [8-11]. As a viral deubiquitinating. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lin et al. Journal of Biomedical Science 2014, 21:54 Page 2 of 8
http://www.jbiomedsci.com/content/21/1/54protease (DUB), MERS-CoV PLpro is able to deubiquitinate
interferon regulatory factor 3 (IRF3), which can prevent its
nuclear translocation and suppress production of inter-
feron β [10]. These studies support the multifunctional na-
ture of coronaviral PLpro. Recently, with the crystal
structure of SARS-CoV PLpro C112S mutant in complex
with ubiquitin (Ub), we have demonstrated that Ub core
(residue 1–72) makes mostly hydrophilic interactions with
PLpro, while the Leu-Arg-Gly-Gly C-terminus of Ub is lo-
cated in the catalytic cleft of PLpro, mimicking the P4-P1
residues [12]. This bound pattern is similar to that of the
ubiquitin-specific proteases (USPs), one of the five distinct
DUB families [13,14].
The MERS-CoV PLpro domain in nsp3 of the pp1a
proteins (residue 1484–1800) has been identified [7,10,15].
Like other PLpro, there is a catalytic triad consisting of the
residues Cys1592, His1759 and Asp1774. Homology mod-
eling suggests that MERS-CoV PLpro, similar to other
known PLpro, may have a right-hand-like architecture con-
stituted by palm, thumb, and fingers domains, although
their sequence identity are only about 30% [12]. Further-
more, MERS-CoV PLpro is able to recognize and cleave at
the LXGG consensus cleavage site, which is essential for
most CoV PLpro-mediated processing [10]. Despite this
large body of knowledge on MERS-CoV PLpro, in the ab-
sence of detailed structural and functional characterization,
the molecular basis for its catalytic mechanism remains
poorly unknown.
Here, we expressed and purified the MERS-CoV PLpro
by E. coli with high yield and high purity. The secondary,
tertiary and quaternary structure of MERS-CoV PLpro
was then investigated by circular dichroism (CD) spec-
troscopy, Tyr/Trp fluoresecence and analytical ultracen-
trifugation (AUC), respectively. The kinetic and DUB
activity assays indicated that MERS-CoV PLpro exhibits
potent DUB activity but lower proteolytic activity, com-
pared with SARS-CoV PLpro. The present study provides
a foundation for understanding the structural and bio-
chemical properties of coronaviral PLpro family, which is
applicable to develop strategies inhibiting PLpro for the ef-
fective control of highly pathogenic coronaviral infection.
Methods
Expression plasmid construction
The sequence of MERS-CoV PLpro (GenBank accession
number NC_019843.2; polyprotein residues 1484–1800)
was synthesized (MDBio Inc.), digested by NcoI-XhoI and
then inserted into the pET-28a(+) vector (Novagen). In the
construct, the 6 x His tag was retained at the C-terminus.
The reading frame was confirmed by sequencing.
Expression and purification of MERS-CoV PLpro
The expression vector was transformed into E. coli BL21
(DE3) cells (Novagen). For large scaled protein expression,cultures were grown in LB medium of 0.8 liter at 37°C
for 4 h, induced with 0.4 mM isopropyl-β-D-thio-
galactopyranoside, and incubated overnight at 20°C. After
centrifuging at 6,000 x g at 4°C for 15 min, the cell pellets
were resuspended in lysis buffer (20 mM Tris, pH 8.5,
250 mM NaCl, 5% glycerol, 0.2% Triton X-100, and 2 mM
β-mercaptoethanol) and then lysed by sonication. The
crude extract was then centrifuged at 12,000 x g at 4°C for
25 min to remove the insoluble pellet. The supernatant
was incubated with 1-ml Ni-NTA beads at 4°C for 1 h and
then loaded into an empty column. After allowing the
supernatant to flow through, the beads were washed with
washing buffer (20 mM Tris, pH 8.5, 250 mM NaCl,
8 mM imidazole, and 2 mM β-mercaptoethanol), and the
protein was eluted with elution buffer (20 mM Tris,
pH 8.5, 30 mM NaCl, 150 mM imidazole, and 2 mM
β-mercaptoethanol). The protein was then loaded onto a
S-100 gel-filtration column (GE Healthcare) equilibrated
with running buffer (20 mM Tris, pH 8.5, 100 mM NaCl,
and 2 mM dithiothreitol). The purity of the fractions col-
lected was analyzed by SDS-PAGE and the protein was
concentrated to 30 mg/ml by Amicon Ultra-4 10-kDa cen-
trifugal filter (Millipore).
Circular dichroism spectroscopy
CD spectra of the recombinant MERS-CoV PLpro using
a JASCO J-810 spectropolarimeter showed measure-
ments from 250 to 190 nm at 20°C in 50 mM phosphate
pH 6.5. The protein concentration was 1.0 mg/ml. In
wavelength scanning, the width of the cuvette was 0.1 mm.
The far-UV CD spectrum data were analyzed with the
CDSSTR program [16,17]. In this analysis, the α-helix,
β-sheet, and random coil were split. To estimate the
goodness-of-fit, the normalized root mean square devi-
ation was calculated.
Spectrofluorimetric analysis
The fluorescence spectra of the enzyme at 1 μM were
monitored in a Perkin-Elmer LS50B luminescence spec-
trometer at 25°C. The excitation wavelength was set at
280 nm, and the fluorescence emission spectrum was
scanned from 300 to 400 nm. Measurement in the max-
imal peak, intensity, and average emission wavelength
were used to confirm the protein folding [18,19].
Analytical ultracentrifugation analysis
The AUC experiments were performed on a XL-A ana-
lytical ultracentrifuge (Beckman Coulter) using an An-50
Ti rotor [12,19-22]. The sedimentation velocity ex-
periments were performed using a double-sector epon
charcoal-filled centerpiece at 20°C with a rotor speed
of 42,000 rpm. Protein solutions of MERS-CoV PLpro
(1.0 mg/ml) (330 μl) and reference (370 μl) solutions were
loaded into the centerpiece, respectively. The absorbance
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time interval of 300 s and a step size of 0.003 cm. Multiple
scans at different time intervals were then fitted to a con-
tinuous c(s) distribution model using the SEDFIT program
[23]. All size-and-shape distributions were analyzed
at a confidence level of p = 0.95 by maximal entropy
regularization and a resolution N of 200 with sedimen-
tation coefficients between 0 and 20 S or molar mass
between 0 and 1000 kDa.
Steady-state kinetic analysis
The peptidyl substrate, Dabcyl–FRLKGGAPIKGV–Edans,
was used to measure the enzymatic activity of MERS-CoV
PLpro and its mutants throughout the course of the study
as described [24]. Specifically, the enhanced fluorescence
emission upon substrate cleavage was monitored at excita-
tion and emission wavelengths of 329 and 520 nm, respect-
ively, in a PerkinElmer LS 50B luminescence spectrometer.
Fluorescence intensity was converted to the amount of hy-
drolyzed substrate using a standard curve drawn from the
fluorescence measurements of well-defined concentrations
of Dabcyl–FRLKGG and APIKGV–Edans peptides in a 1:1
ratio. This will also correct for the inner filter effect of the
substrate. For the kinetic analysis, the reaction mixture
contained 4–50 μM peptide substrate in 50 mM phosphate
pH 6.5 in a total volume of 1 mL. After the addition of the
enzyme to the reaction mixture, the increase in fluores-
cence was continuously monitored at 30°C. The increase in
fluorescence was linear for at least 3 min, and thus the
slope of the line represented the initial velocity (v). TheFigure 1 Expression and purification of recombinant MERS-CoV PLpro. (
cytoplasmic fraction, flow-through, elution from the nickel affinity column and
sequence identification by mass spectrometry. The PLpro was digested by tr
matched peptides observed (B) and 60% sequence coverage are shown insteady-state kinetic parameters of the enzyme were de-
termined by fitting the Michaelis–Menten equation
(eq. 1) to the initial velocity data
v ¼ kcat E½  S½ 
Km þ S½  ð1Þ
in which kcat is the rate constant, [E] and [S] denote the
enzyme and substrate concentration, and Km is the
Michaelis-Menten constant for the interaction between
the peptide substrate and the enzyme.
Deubiquitination assay
The fluorogenic substrate Ub-7-amino-4-trifluoro-methyl-
coumarin (Ub-AFC) (Boston Biochem) added at 0.5 or
1.0 μM to 50 mM phosphate pH 6.5 was used for deubi-
quitination assays as described [12]. The enzymatic activity
at 30°C was determined by continuously monitoring the
fluorescence emission and excitation wavelength of 350
and 485 nm, respectively.
Results and discussion
Recombinant MERS-CoV PLpro preparation
To date, there are still no studies describing the expres-
sion and purification of MERS-CoV PLpro proteins. In
the present study, the expression vector was constructed
and then various E. coli. strains such as BL21 (DE3)
STAR (Invitrogen) and Rosetta (DE3) (Novagen) were
used to explore heterologous expression of MERS-CoV
PLpro. Finally, it was found that the STAR strain showedA) Protein identification by SDS-PAGE. M: molecular marker. Lane 1–4:
protein fraction from S-100 gel-filtration column. (B) and (C) Protein
ypsin and then analyzed by MALDI mass spectrometry. There are 15
bold red (C).
Table 1 Purification of MERS-CoV PLpro from E. coli
Step Total protein (mg) Total activity (Ua) Specific activity (U/mg protein) Purification (−fold) Recovery (%)
Cytoplasmic fraction 426 340 0.80 1 100
Ni affinity chromatography 64.4 221 3.43 4.3 65
Gel-filtration by S-100 column 41.9 168 4.01 5.0 49.4
aOne unit is defined as the amount of enzyme required to catalyze the cleavage of 1 nmole of peptidyl substrate (Dabcyl-FRLKGGAPIKGV-Edans) per minute at 30°C.
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tein in E. coli and purification by nickel affinity chroma-
tography and gel-filtration, the purity of recombinant
PLpro was about 99% (Figure 1A). The size of the recom-
binant MERS-CoV PLpro was found to be between 30
and 45 kDa, which conforms to the theoretical mass
(36.5 kDa). The typical yield was about 42 mg after puri-
fication from 0.8 liter of E. coli culture (Table 1). After
gel-filtration chromatography, the specific proteolytic activ-
ity of PLpro was 4 U/mg, increased by 5-fold, with 49.4%
recovery rate.
Furthermore, the recombinant MERS-CoV PLpro
was digested by trypsin and then analyzed by MALDI
mass spectrometry to confirm the amino acid sequence
(Additional file 1: Figure S1). The molecular weight of fif-
teen peptides, which covered 60% amino acid sequence,
was observed and confirmed (Figure 1B and Figure 1C). It
indicated that our expression and purification of MERS-
CoV PLpro by E. coli is successful. For convenience, in the
present studies, the MERS-CoV PLpro domain (polyprotein
1a 1484–1800) is numbered to residue 2 to 317, while the
first residue is a methionine.Figure 2 CD spectrum of MERS-CoV PLpro. The protein of 1 mg/ml
was suspended in 50 mM phosphate pH 6.5 and the CD values were
measured from 240 to 190 nm at 20°C. The obtained spectrum is
shown as close circles and the best fit by CDSSTR [16] is shown by
solid line. The normalized root mean square deviation is 0.015.Secondary, tertiary and quaternary structure analysis of
MERS-CoV PLpro
Next, secondary, tertiary and quaternary structures of
MERS-CoV PLpro were investigated, respectively. CD
measurement displayed a spectrum which shows nega-
tive ellipticity between 240 and 205 nm and positive be-
tween 205 and 190 nm (Figure 2). After analyzed by
CDSSTR method [16], the best-fit result showed that
MERS-CoV PLpro has 23% of α-helix, 31% of β-sheet,
and 46% of random coil. The consist is close to that of
SARS-CoV PLpro (pdb code: 4M0W) by X-ray crystallog-
raphy, which has 26% of α-helix, 36% of β-sheet, and
38% of random coil [12]. It suggests that both PLpro may
have a similar scaffold.
The Tyr/Trp fluorescence of MERS-CoV PLpro at
the phosphate buffer without or with 9 M urea were
also identified (Figure 3). The measurement indicated
that the fluorescent intensity of native PLpro (Figure 3,
close circles) shows a 70% increase, as compared with
that of the denatured form in urea (Figure 3, open circles).
On the other hand, the fluorescence emission spectrum
of the native MERS-CoV PLpro shows a maximum at
336 nm, while that of the unfolded one shifts to
340 nm. The tendency is similar to that of SARS-CoV
PLpro [19] and suggests a folded structure. Next, we
also performed AUC experiments to characterize theFigure 3 Fluorescence spectrum of MERS-CoV PLpro. The protein
of 1 μM was dissolved in 50 mM phosphate pH 6.5 (closed circles)
or 9 M urea (open circles) and excited with 280 nm UV light. The
protein fluorescence emission was monitored from 300 to 400 nm
at 25°C.
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shows a typical absorbance trace at 280 nm of the
PLpro during the experiment. After fitting the signals
to a continuous size-distribution model, it was clear that
the PLpro was monomeric with a sedimentation coeffi-
cient of 2.8 S and molar mass of 35.5 kDa (Figure 4B and
Figure 4C), consistent with that for SARS-CoV PLpro
[12,19]. All of these biophysical observation confirmed
that the PLpro of MERS-CoV and SARS-CoV should have
a very similar structure; albeit they only show 30% se-
quence identity and 50% similarity [12]. Recent studies
hypothesized that the homology model of MERS-CoV
PLpro, like other coronaviral PLpro, is a right-hand-
like architecture consisting of palm, thumb and fingers
domains [10,25].Figure 4 The continuous size distribution change of MERS-CoV
PLpro. (A) Traces of absorbance at 280 nm of the enzyme in the
50 mM phosphate pH 6.5 during the SV experiment. The protein
concentration was 1 mg/ml. For clarity, only every four scan is
shown. The symbols represent experimental data and the lines are
the results obtained after fitted to the Lamm equation using the
SEDFIT program [23,26]. (B) and (C) show the continuous c(s) and c(M)
distribution of PLpro, respectively. The residual bitmap of the raw data
and the best-fit results are shown in the inset.Proteolytic activity of MERS-CoV PLpro
Besides the structural similarity, previous studies have
suggested that MERS-CoV PLpro is also a multifunc-
tional enzyme with protease, deubiquitinating and inter-
feron antagonist activities [10]. MERS-CoV PLpro has a
catalytic triad which is able to recognize and cleave at
LXGG consensus cleavage sites; however, the detail en-
zyme kinetic mechanism is not known. Here we used
the peptidyl substrate, Dabcyl–FRLKGGAPIKGV–Edans,
to measure the proteolytic activity of MERS-CoV PLpro
(Figure 5A and Table 2). Interestingly, compared with thatFigure 5 Proteolytic and DUB activity assay of MERS-CoV PLpro
and its mutants. Panel (A) shows the plot of initial velocities versus
the concentration of peptidyl substrate, Dabcyl-FRLKGGAPIKGV-Edans.
The concentration of the wild-type MERS-CoV PLpro (by circles), the
L105W (by triangles) and P162L mutants (by squares) was 1, 0.1 and
10 μM, respectively. The line represented the best-fit results according
to the Michaelis-Menten equation (Eq. 1). The kinetic parameters
derived are shown in Table 2. (B) DUB activity analysis. The fluorogenic
substrate Ub-AFC (1 μM) was used as the substrate. For comparison,
both DUB activity of SARS-CoV and MERS-CoV PLpro was tested. The
protein concentration was 0.17 μM. Besides, the inhibition of MERS-CoV
PLpro by 10–50 mM EDTA or 50 μM Zn2+ were also clarified.
Table 2 The kinetic parameters and DUB activity of
MERS-CoV PLpro
Proteins Peptide cleavage Deubiquitination
Km kcat kcat/Km Activity
(Intensity/s)b(μM)a (10−2 s−1)a (10−3 s−1 μM−1)
MERS-CoV
PLpro
Wild-type 19.2 ± 2.6 0.4 ± 0.02 0.2 ± 0.03 0.11 ± 0.02
L105W
mutant
35.7 ± 3.8 16.5 ± 0.9 4.6 ± 0.6 0.11 ± 0.01
P162L
mutant
30.8 ± 8.0 0.01 ± 0.001 0.003 ± 0.001 0.004 ± 0.001
SARS-CoV
PLpro
25.2 ± 5.1c 11 ± 2c 4.4 ± 1.2c 0.12 ± 0.02
aKinetic data of MERS-CoV PLpro and its mutants were fitted to the Michaelis-
Menten equation (Eq. 1). The Rsqr were from 0.986 to 0.997, respectively. All
the assays were repeated several times to ensure reproducibility.
bFixed concentrations of Ub-AFC (0.5 μM) and PLpro (0.17 μM) were used.
cThe values were from our previous studies [24].
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fold loss in kcat/Km, as a result of a 27.5-fold loss in kcat
and 1.3-fold loss in Km. According to the sequence align-
ment and homology modeling, most important residues
for the catalysis, including the catalytic triad, Cys110-
His277-Asp292 and the residues for substrate P4-P1 bind-
ing, Asp164, Pro249, and Gly276 (Asp165, Pro249, and
Gly272 in SARS-CoV PLpro) are highly conserved (Figure 6)
[10,12]. Previous studies have confirmed that Y265F mu-
tant of SARS-CoV PLpro still maintained comparable pro-
teolytic activity with the wild-type [12]. It indicates that the
equivalent residue in MERS-CoV PLpro, Phe268, is able toFigure 6 Putative active site of MERS-CoV PLpro. The model structure o
then overlaid with the structure of SARS-CoV PLpro (in grey) in complex wit
and hydrogen bonding and ion-pair interactions are indicated by red dash
Tyr269, are labeled in black. The figure was produced using PyMol (http://wmake a hydrophobic contact with the substrate P4 residue
(Ub-Leu73). Furthermore, although different to the residue
Tyr269 of SARS-CoV PLpro, the equivalent residue Glu272
of MERS-CoV PLpro, whose carboxyl group can point to-
ward outside the hydrophobic pocket, may not interfere
the binding of substrate P4 residue (Figure 6). By contrast,
as a putative oxyanion bound residue (Tyr107 in SARS-
CoV PLpro) [15], the equivalent residue Leu105 of MERS-
CoV PLpro cannot provide any hydrogen bonding inter-
action with oxyanion (Figure 6). It will disfavor the forma-
tion of tetrahedral intermediate. Otherwise, different to the
Leu163 of SARS-CoV PLpro, the distinct circular structure
of the equivalent residue Pro162 of MERS-CoV PLpro may
be too short to hover above the active site for substrate
binding and serve to enhance the nucleophilicity of the
catalytic triad residue, Cys110 (Figure 6). These two point
mutations in MERS-CoV PLpro may significantly lower the
catalytic efficiency.
To verify this, we produced the L105W and P162L
mutants of MERS-CoV PLpro, and our kinetic data
showed that the L105W mutant has a 23-fold increase
in activity measured based on kcat/Km, as a result of
a 41-fold increase in kcat and 1.9-fold increase in Km
(Figure 5A and Table 2). The results conform to our
prediction. However, in contrast, the P162L mutant has a
67-fold loss in kcat/Km, as a result of a 40-fold loss in kcat
and 1.6-fold increase in Km (Figure 5A and Table 2). It
suggests the requirement of the Proline residue in this
site, although the reason is still not known. Nevertheless,
the significant activity recovery by L105W mutation con-
firms the essential role of this residue on coronaviral
PLpro catalysis. Theoretically, PLpro with lower proteolyticf MERS-CoV PLpro (in cyan) was generated by SWISS-MODEL [27] and
h Ub (in yellow) (PDB code: 4M0W). The residues are shown as sticks
ed lines. Four residues of SARS-CoV PLpro, Trp107, Leu163, Tyr265 and
ww.pymol.org).
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and nsp3 proteins; nonetheless, its influence on MERS-
CoV remains unknown.
DUB activity of MERS-CoV PLpro
To characterize the DUB activity of MERS-CoV PLpro,
the fluorogenic substrate Ub-AFC was used. Interest-
ingly, in contrast with its rather low proteolytic activity,
MERS-CoV PLpro shows comparable DUB activity to
SARS-CoV PLpro (Table 2 and Figure 5B). It suggests
that the two PLpro may show similar binding ability to
the Ub core domain (residue 1–72). However, it is in-
consistent with our previous observation on the struc-
ture of SARS-CoV PLpro in complex with Ub [12]. As
mimicking the equivalent residue of MERS-CoV PLpro,
the arginine mutation of a key residue for Ub core do-
main binding, Glu168, can result in unstable binding of
SARS-CoV PLpro and Ub and significant loss of DUB activ-
ity [12]. To verify this inconsistency, a structure of MERS-
CoV PLpro in complex with Ub is quite necessary.
Structural characterization of type 1 and type 2 PLpro
have revealed that there are four cysteine residues co-
ordinating to a zinc ion within the fingertips region in
the finger domain [25,28]. Remove of zinc from SARS-
CoV PLpro will cause the tertiary structure more un-
stable and lead to less active [19]. Based on sequence
alignment, MERS-CoV PLpro also has four cysteine resi-
dues (Cys190, Cys193, Cys225 and Cys227) on the corre-
sponding position. Here the DUB activity of MERS-CoV
PLpro in various EDTA was examined to delineate the
possible metal ion effect. The activity was 79% in 10 mM,
and 72% left in 50 mM EDTA (Figure 5B). These results
suggest the existence of endogenous metal ion, which is
beneficial for its DUB activity. By the way, it has been clari-
fied that exogenous zinc ion can efficiently inhibit SARS-
CoV PLpro with the IC50 value of 1.3 μM [24,29]. Here we
also confirmed the potent inhibitory effect of zinc ion on
MERS-CoV PLpro (Figure 5B); whereas the mechanism of
this inhibition by zinc is not yet understood.
Conclusions
In summary, following our protocol, active MERS-CoV
PLpro can be expressed by E. coli and purified with high
yield and high purity. The secondary, tertiary and qua-
ternary structural studies concluded that MERS-CoV
PLpro has a similar scaffold to other coronaviral PLpro, as
a right-hand-like architecture consisting of palm, thumb
and fingers domains. The result of functional assay indi-
cated that MERS-CoV PLpro exhibits potent DUB ac-
tivity but rather low proteolytic activity. A natural
mutation, Leu105, is the major reason for this difference.
The present study not only demonstrates the structural
and functional characterization of MERS-CoV PLpro,
but provides a foundation for further understanding thecoronaviral PLpro family, which is an ideal antiviral target.
Next, with pure protein and effective proteolytic activity
assay, potent inhibitors of MERS-CoV PLpro can be high
throughput screened and identified.
Additional file
Additional file 1: Figure S1. Mass spectrometry of trypsin-digested
peptides of the recombinant MERS-CoV PLpro protein. The red peaks
show the signals of the peptides with correct mass, while the blue ones
show the signals of the peptides with oxidation. X-axis indicates the m/z
ratio and Y-axis shows the absorbance intensity.
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